Regen BioPharma Inc (RGBP)

[Musical Shares]

Not really.

There were no extra steps. The significant expense was just normal compensation to an auditing firm - like many, many companies have to do and pay. It would be most prudent of Regen to use the money wisely given from Oncology Pharma. That would be getting current.

As far as to why...

There are a number of factors that played into Regens hands this year.

The most prevalent is the pandemic. It brought out the household name of "mRNA." This little, but certainly not new, medical field was quietly (for the most part) "under the radar" since about mid 2000's.

There are literally numerous companies that have been working on mRNA products, mRNA cancer vaccines and mRNA vaccines since this time.

The problem, like so much in the pharmaceutical field, is the challenges of this technology. As for mRNA cancer vaccines, efficacy of such vaccinations was a major hurdle, along with the actual development of "tricking" the tumor cancer cells. And it still is.

What Covid did was make the world believe that an mRNA vaccine could safely and effectively work on millions - and it was achieved.

What Regen has now in their hands is POTENTIAL. NOT A PROMISE.

Their proprietary checkpoint inhibitor NR2F6 is another wonderful addition in their POTENTIAL IP portfolio. This checkpoint has been given another serious look at this year and is in the category of emerging next-generation target for cancer immunotherapy research.

What Regen has is a possible mRNA cancer vaccine patent and intracellular checkpoint NR2F6 patent.

All the best.